Christopher John Kenney Sells 2,771 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $166,564.81. Following the completion of the sale, the insider directly owned 4,729 shares in the company, valued at $284,260.19. This represents a 36.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Xenon Pharmaceuticals Stock Performance

Shares of XENE opened at $57.90 on Friday. The stock has a 50 day moving average price of $43.49 and a 200 day moving average price of $41.80. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $63.95. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of -13.28 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the firm posted ($0.84) earnings per share. On average, analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on XENE. Bank of America reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday. Needham & Company LLC increased their price objective on shares of Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a report on Monday. Wedbush raised their target price on shares of Xenon Pharmaceuticals from $47.00 to $64.00 and gave the stock an “outperform” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Finally, Wolfe Research started coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $71.94.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Closed upsized offering — Xenon completed an upsized public offering that raised roughly $747.5M (including full exercise of the underwriters’ option), providing substantial cash to fund Phase‑3 activities, NDA planning and early commercial buildout, and materially lowering near‑term financing risk. GlobeNewswire: Closing of Offering
• Positive Sentiment: Clinical derisking — Xenon’s lead candidate azetukalner posted a positive Phase‑3 efficacy readout in focal‑onset seizures and management plans an NDA filing in 2026, which increases the program’s near‑term commercial value and supports upside case assumptions. Zacks: Azetukalner Study
• Positive Sentiment: Analyst support rising — Multiple brokerages raised price targets and maintained buy/overweight stances (examples: Deutsche Bank, HC Wainwright, Wells Fargo), which can attract momentum buyers and institutional interest. Deutsche Bank PT HC Wainwright Note
• Neutral Sentiment: Model updates — HC Wainwright adjusted multi‑year EPS forecasts (improving FY2028–FY2030 but nudging FY2027 worse), reflecting shifting timing/commercial assumptions; useful for modeling but still speculative. HC Wainwright EPS Revision
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (CEO sold ~270k shares; additional insiders sold smaller blocks), which reduces insider ownership and may concern some investors about timing/liquidity taking. SEC Filing: Insider Sales
• Negative Sentiment: Dilution risk — the large share issuance (and pre‑funded warrants / potential additional option shares) increases outstanding share count and can pressure near‑term per‑share metrics and valuation multiples despite the stronger cash position. GlobeNewswire: Closing of Offering

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Holocene Advisors LP purchased a new position in Xenon Pharmaceuticals during the second quarter worth about $56,637,000. Wellington Management Group LLP boosted its holdings in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Xenon Pharmaceuticals by 1,294.2% in the 2nd quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after buying an additional 900,746 shares during the period. Braidwell LP grew its stake in shares of Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after buying an additional 895,154 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Xenon Pharmaceuticals by 1,968.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after buying an additional 820,608 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.